Vozmozhnosti terapii erektil'noy disfunktsii neyrogennogo geneza ingibitorami fosfodiesterazy 5-go tipa u bol'nykh sakharnym diabetom
- Authors: Kurbatov DG1, Rozhivanov RV1
-
Affiliations:
- Issue: No 5 (2009)
- Pages: 48-
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277566
- ID: 277566
Cite item
Full Text
Abstract
We performed a pilot study of PDE-5 inhibitors efficacy in the treatment of diabetic genital neuropathy. A total of 16 diabetic males (type 1 diabetes mellitus) having erectile dysfunction with symptoms of genital neuropathy entered the trial. These patients received tadalafil for 3 months. The results were assessed with sexological questionnaires and dynamics of genital neuropathy symptoms. Tadalafil treatment was found effective.
References
- Mostafa Т. Oral phosphodiesterase type 5 inhibitors: Nonerectogenic beneficial uses. J. Sex. Med. 2008; 5: 2502-2518.
- Garcia E. L., Moncada I. I., Rascon J. J. et al. Treatment with sildenafil of cold glands syndrome after inflatable penile prosthesis. Actas Urol. Esp. 2004; 28: 443-446.
- Коган М. И. (ред.). Нарушения половой функции у мужчин при сахарном диабете. М.; 2005.
- Hackett G. PDE5 inhibitors in diabetic peripheral neuropathy. Int. J. Clin. Pract. 2006; 60: 1123-1126.
- Rozhivanov R. V., Kalinchenko S. Yu. Neurological criteria of neurogenic erectile dysfunction diagnostics in patients with diabetes. Andrologia 2004; 36 (4): 193.
Supplementary files
